Gender	Male
E-mail	vahram.haroutunian@mssm.edu

Dr. Haroutunian joined the faculty at The Mount Sinai School of Medicine in the summer of 1982 and is now Professor of Psychiatry and Neurobiology. Dr. Haroutunian came to Mount Sinai after completing a postdoctoral training program at Princeton concentrating on research in development and in aging. His research interests since joining the Mount Sinai faculty have centered on the neurobiology of Alzheimer??s disease and schizophrenia. He directs the Division of Basic and Laboratory Science in the Department of Psychiatry, the Alzheimer??s disease and Schizophrenia Brain Bank, a National Institute of Aging program project grant entitled Clinical and Biological Studies of Early Alzheimer??s disease, a National Institute of Mental Health R01 grant and a Veterans Affairs Merit grant on the roles of glutamate in schizophrenia, and is the Associate Director for Research for the Veterans Administration Mental Illness Research and Education Clinical Center. He is also a major contributor to Mount Sinai??s Silvio Conte Center for Neuroscience and the Alzheimer??s disease Research Center. In the past decade Dr. Haroutunian??s research has centered on clinical and neuropathological correlated of schizophrenia and dementia. He has used molecular biological techniques, including microarray technology (DNA-chip) and neuropathological studies to understand the biological substrates of mental illness and dementia. Dr. Haroutunian works closely with his associates and colleagues Dr. Stella Dracheva and Dr. Pavel Katsel and collaborates with many members of the Department of Psychiatry and researchers at Mount Sinai and multiple other institutions in the US and around the world. These collaborations include studies conducted jointly with Dr. Kenneth Davis, Dr. Joseph Buxbaum, Dr. Giulio Pasinetti, Dr. Gregory Elder and Dr. Philip Harvey.

Haroutunian V, Perl DP, Purohit DP, Marin D, Khan K, Lantz M, Davis KL, Mohs RC. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol 1998; 55(9): 1185-1191.

Haroutunian V, Purohit DP, Perl DP, Marin DB, Khan K, Lantz M, Davis KL, Mohs RC. Neurofibrillary tangles in nondemented elderly and very mild Alzheimer's disease. Arch Neurol 1999; 57: 713-718.

Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999; 281(15): 1401-1406.

Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000; 283: 1571-1577.

Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A 2001; 98(8): 4746-4751.

Dracheva S, Marras SA, Elhakem SL, Kramer FR, Davis KL, Haroutunian V. N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry 2001; 158(9): 1400-1410.

Haroutunian V, Davis KL. Pathophysiology of Dementia. In: Tasman A, Kay J, Lieberman J, editors. Psychiatry. Chichester, England, John Wiley & Sons; 2003. pp338-349.

Davis KL, Haroutunian V. Global expression-profiling studies and oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003; 362(9386): 758.

Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof P, Buxbaum JD, Haroutunian V. White matter changes in schizophrenia: Evidence for myelin-related dysfunction. Arc Gen Psychiatry 2003; 60: 443-456.